Ernest Lim's investing blog

Unique insights into SGX small caps

Ernest

Markets – possible technical rebound in the near term but likely short lived (26 May 2022)

el15

Dear all I have been extremely busy with work, hence the dearth of articles on my blog. Dow has closed lower for the eighth consecutive week. This marks the longest period of consecutive weekly losses since 1923! S&P500 has registered a seventh week of losses, its longest weekly losing streak since March 2001. Are the markets going to drop into an abyss? Or has the bottom been reached? Before we delve into this, let’s recap on my earlier market outlook article dated 4 Apr 22 (click HERE). Previously, I wrote that I am more inclined towards the bearish / prudent […]

Aztech looks interesting – lowest forward PE among SG tech stocks with a 5.6% estimated dividend yield! (16 Apr 22)

el15

Dear all This week, Aztech has caught my attention amid rising volume with its 1QFY22F business update just around the corner. It has fallen approximately 39% from an intraday high of $1.56 on 27 Apr 2021 to close at $0.950 last Thursday. Let’s take a look on the interesting points and potential risks on Aztech.   Interesting points a) Analysts like Aztech with average target price $1.44 With reference to Figure 1 below, 4 analysts cover Aztech and all rate it a buy. Average analyst target price is around $1.44. If the analysts are right, Aztech offers a potential capital […]

Markets – diverging signs from technicals and fundamentals. What should we do? (4 Apr 2022)

el15

Dear all March has been a roller coaster month. Hong Kong market, represented by Hang Seng index touched multi-year lows around 14-15 Mar and has rebounded approximately 21% from the intraday lows. S&P500 performed well too with a third consecutive weekly rise. With reference to my writeup (click HERE) published on 6 Mar 2022, I mentioned that a) Odds are likely of a downward push first I mentioned that based on chart, odds are higher for a downwards move for both S&P500 and STI, to retest the previous support around 4,115 – 4,222 and 3,138 – 3,200 (with 3,175 a […]

Markets may continue to be volatile but also present valuable opportunities ahead (6 Mar 2022)

el15

Dear all We are two months into 2022. How is your portfolio doing? With reference to my writeup (click HERE) published on 17 Feb 2022, I mentioned that STI is likely to face headwinds in the near-term and SG banks’ share prices are likely to peak around 7-18 Feb based on past observations.   Coincidentally a) STI peaked on 17 Feb. In fact, STI has tumbled 6.9%, or 239 pts from its intraday high 3,466 on 17 Feb to close 3,227on 4 Mar. Last Friday’s intraday low was 3,208. More about its chart below. b) Banks – DBS peaked on […]

AEM enters bear market despite analysts’ positive calls. What gives? (20 Feb 22)

el15

Dear all AEM has fallen 21% from an intraday high of $5.37 on 14 Dec 2021 to close $4.25 on 18 Feb 2022. What has happened in the last two months to warrant such falls? Based on Bloomberg, average analyst target price is around $6.72, representing a potential capital upside of around 58%. Is this the bottom for AEM, or will it fall further? Personally, I think AEM is worth a closer look at $4.20 – 4.30 region. Let’s take a look at its investment merits and risks.   First things first, what does AEM do? According to its company […]

STI is up 10.1% YTD; may face profit taking in the near-term (16 Feb 2022)

el15

Dear all STI has been on a tear since the start of the year. With reference to my write-up published on 5 Jan 2022 (click HERE) citing that Asian indices are likely to outperform that of the U.S. market in 2022, STI has indeed notched strong year to date (“YTD”) gains of 10.1% to close 3,439 on 16 Feb 2022. This outperformance is especially stark if we compare it to S&P500’s -6.1% YTD returns. As I have shared with Lianhe Zaobao on 9 Feb 2022, I personally feel that our STI is overbought in the near term with several near-term […]

Sing Medical – Trades at a 13-month low price despite posting record 1HFY21 results (3 Feb 22)

el15

Dear all On 29 Dec 2020, I have published a write-up on Sing Medical (“SMG”) where I outlined that the risk reward on SMG seems favourable at $0.315, given a potential share transaction scenario (click HERE). Since 29 Dec, SMG rose approximately 32% to trade $0.415 – 0.420 on several occasions in Feb 2021. Subsequently, it dropped sharply in Apr 2021 when it announced that the potential share transaction has lapsed. Fast forward to 31 Jan 2022 and SMG closed at a 13-month low at $0.290. This is notwithstanding its sterling record 1HFY21 results announced in Aug last year where […]

GSS Energy – Electric mobility business takes shape (25 Jan 22)

el15

Dear all, With reference to my write-up published on 5 Jan 2022 (click HERE) citing that Asian indices are likely to outperform that of the U.S. market in 2022, our Asian indices, viz. Hang Seng and STI have outperformed the U.S. market significantly (See Table 1 below). U.S. S&P500 notched a 6.4% decline whereas Hang Seng and STI registered a 9.0% and 4.2% gain respectively since my write-up. Table 1: S&P500, Hang Seng and STI 2021 performance since 5 Jan 2022 Source: Ernest’s compilation Given the outperformance, are there still pockets of opportunities in our Singapore market? The short answer […]

Will Singapore stocks outperform U.S. stocks in 2022? (5 Jan 2022)

el15

Dear all With reference to my market outlook published on 7 Nov (see HERE) citing our Singapore market may face near term profit taking, STI dropped 201 points, or 6.6% from 3,242 on 5 Nov to close at 3,041 on 30 Nov. As we start 2022, various investment banks and research houses have put forth their views on how the various markets will perform. In this write-up, I will share how the markets have performed in 2021 and my market outlook in 2022.   How did the markets perform in 2021? Based on Table 1 below, it is evident that […]

STI – having closed at a record YTD high, will it continue higher? (7 Nov 2021)

el15

Dear all With reference to my market outlook published on 3 Oct (see HERE) citing opportunities in our Singapore market, STI has soared 191 points, or 6.3% from 3,051 on 1 Oct to close at a year to date high 3,242 on 5 Nov. Will STI continue to march higher, or will there be some profit taking?   Very briefly, my personal view is It is likely that STI may face some profit taking in the near term, attributable in part to the following factors: a) With reference to Figure 1 below, MSCI Singapore index will undergo a rebalancing in […]